IMMUNOSCORE® IC, as a member of the IMMUNOSCORE® family assays, is a standardized Immunohistochemistry (IHC)-based assay.
In addition, HalioDx provides image and data analysis services allowing standardized quantification of both PD-L1+ and CD8+ cell populations and the assessment of cells clustering as well as a proximity index. These measures aim to help identifying which NSCLC patients may best respond to anti-PD1 or anti-PD-L1 immunotherapies.
IMMUNOSCORE® IC is available as a CE-IVD assay for PD-L1+ cells detection and as an RUO* solution in the Rest of The World through our comprehensive offer integrating HalioDx service laboratory.
* For Research Use Only. Not for use in diagnostic procedures.
IMMUNOSCORE® IC solution consists in two parts:
IMMUNOSCORE® IC is intended to help clinicians defining immunotherapy treatment strategy for patients with NSCLC.
Anti-PD-1/PD-L1 are now established treatments for advanced NSCLC patients; however, PD-L1 predictive value is not optimal. Association of PD-L1 + TC % with the assessment of tumor-infiltrating lymphocytes (TILs) via CD8+ T cells quantification and proximity measurement should improve the selection of patients likely to respond to Immune Checkpoint Inhibitors treatment.
Depending on your laboratory equipment IMMUNOSCORE® IC is available as a CE-IVD test (Europe only) for PD-L1 assessment directly in your laboratory or in a full service process (performed in HalioDx laboratories) through a standardized and validated workflow. For image analysis services and to access to IMMUNOSCORE® IC documentation, please contact HalioDx.
Classifying Cancers Based on T-cell Infiltration and PD-L1
Cancer Res. 2015
Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nov 27;515(7528):568-71. doi: 10.1038/nature13954
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
Clin Cancer Res. 2014
Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer
Clin Cancer Res. 2013
Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063
The immune contexture in human tumours: impact on clinical outcome
Nat Rev Cancer. 2012
Mar 15;12(4):298-306. doi: 10.1038/nrc3245